Literature DB >> 32247344

Characterization of Acute Prescription Migraine Medication Use: Results From the CaMEO Study.

Susan Hutchinson1, Richard B Lipton2, Jessica Ailani3, Michael L Reed4, Kristina M Fanning4, Aubrey Manack Adams5, Dawn C Buse2.   

Abstract

OBJECTIVE: To characterize self-reported use of acute prescription medication for migraine in a sample representing the US population. PATIENTS AND METHODS: Data were obtained from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. The CaMEO Study is an Internet-based cross-sectional longitudinal survey administered between September 17, 2012, and November 19, 2013. Demographic characteristics, migraine-related disability, symptom severity, quality of life, and psychiatric comorbidity profiles were evaluated.
RESULTS: Data from 13,624 respondents were analyzed, including 3121 (22.9%) self-reported current users of acute prescription medication for migraine, 1719 (12.6%) previous/discontinued users, and 8784 (64.5%) who had never used acute prescription medication for migraine. Mean ± SD monthly headache frequency was 7.3±7.1 days for current users, 5.6±6.6 days for those who discontinued, and 3.9±4.9 days for respondents who never used acute prescription medication for migraine. Current users experienced the highest degree of migraine-related disability based on Migraine Disability Assessment scores and the highest levels of migraine symptom severity based on Migraine Symptom Severity Scale scores. Current users also had the highest scores on the depression and anxiety questionnaires. The most commonly reported prescription medications used or "kept on hand" by current users were triptans (47.2%; 1474 of 3121), opioids (37.3%; 1164 of 3121), nonsteroidal anti-inflammatory drugs (31.9%; 997 of 3121), and barbiturates (12.8%; 399 of 3121), with many people reporting more than 1 medication.
CONCLUSION: Despite reporting moderate to severe migraine-related disability and impairment, many people with migraine have never used acute prescription migraine medication. The burden related to migraine is great, especially among individuals currently using acute prescription medication for migraine.
Copyright © 2019 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2020        PMID: 32247344     DOI: 10.1016/j.mayocp.2019.11.025

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  6 in total

1.  Naturalistic assessment of patterns and predictors of acute headache medication use among women with comorbid migraine and overweight or obesity.

Authors:  Kathryn E Smith; J Graham Thomas; Kristine J Steffen; Richard B Lipton; Samantha G Farris; Jelena M Pavlovic; Dale S Bond
Journal:  Transl Behav Med       Date:  2021-08-13       Impact factor: 3.046

2.  Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 study.

Authors:  Robert P Cowan; Michael J Marmura; Hans-Christoph Diener; Amaal J Starling; Jack Schim; Joe Hirman; Thomas Brevig; Roger Cady
Journal:  J Headache Pain       Date:  2022-09-06       Impact factor: 8.588

3.  Migraine management: an update for the 2020s.

Authors:  Michael Eller; Shuli Cheng
Journal:  Intern Med J       Date:  2022-07       Impact factor: 2.611

4.  STOP 301: A Phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD® ) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients.

Authors:  Timothy R Smith; Paul Winner; Sheena K Aurora; Maria Jeleva; Jasna Hocevar-Trnka; Stephen B Shrewsbury
Journal:  Headache       Date:  2021-08-07       Impact factor: 5.311

5.  Migraine Patients With Cardiovascular Disease and Contraindications: An Analysis of Real-World Claims Data.

Authors:  David W Dodick; Anand S Shewale; Richard B Lipton; Seth J Baum; Steven C Marcus; Stephen D Silberstein; Jelena M Pavlovic; Nathan L Bennett; William B Young; Hema N Viswanathan; Jalpa A Doshi; Howard Weintraub
Journal:  J Prim Care Community Health       Date:  2020 Jan-Dec

Review 6.  A Framework for Estimating the Eligible Patient Population for New Migraine Acute Therapies in the United States.

Authors:  Linda Harris; Gilbert L'Italien; Thomas O'Connell; Zacharia Hasan; Susan Hutchinson; Sylvia Lucas
Journal:  Adv Ther       Date:  2021-05-31       Impact factor: 3.845

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.